Celldex Therapeutics (CLDX) Stock
Clinical stage biotech developing experimental cancer treatments. Here's the price, business snapshot, and what's worth knowing about Celldex Therapeutics in August 2026.
Celldex Therapeutics (CLDX) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies, principally for oncology and immune-related diseases. Investors should know the company’s value stems from a pipeline of experimental candidates that must clear multiple clinical and regulatory milestones before potential commercialisation. With a market capitalisation of about $1.85bn, Celldex is a small-cap biotech and typically more volatile than established pharmaceutical firms. Key upside catalysts include positive clinical trial readouts, regulatory approvals and strategic partnerships; key risks include trial failures, regulatory setbacks, competition and the potential need for additional financing. The stock is generally suited to investors who accept high binary risk, long development timelines and no near-term dividend income. This summary is educational only and not personal advice; values can rise and fall and past performance is not a reliable guide to future returns.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Celldex Therapeutics stock, expecting its value to rise significantly.
Financial Health
CellDex Therapeutics is generating limited revenue and cash flow, indicating modest financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially affect value; positive data may drive upside, though trial outcomes are uncertain.
Binary Clinical Risk
Many biotech outcomes are binary — success or failure in trials — which can lead to sharp share price moves and heightened volatility.
Funding & Partnerships
Partnerships or capital raises can accelerate development or dilute shareholders; monitor announcements that affect cash runway and strategic direction.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
